{"symbol":"JNJ","fiscalQuarter":"Q4-2024","reportDate":"2025-01-22","reportTime":"BMO","status":"reported","company":{"name":"Johnson & Johnson","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/JNJ/earnings/Q4-2024","postBrief":{"headline":"Johnson & Johnson Beats on EPS, Stock Down 1.94%","keyNumbers":[{"metric":"EPS","actual":"$2.04","expected":"N/A","surprise":"+1.85%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted ongoing efforts to streamline operations.","They noted a focus on innovation in their product lines.","There was an emphasis on maintaining strong market positions despite challenges."],"summary":"Management expressed a cautious optimism about future growth. They are focused on operational efficiency and innovation to drive performance."},"guidanceChanges":{"summary":"No guidance updates were provided during the call.","changes":[]},"whatItMeans":"Johnson & Johnson's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by nearly 2% following the announcement, likely due to the lack of revenue data and guidance. Investors may be cautious as the company navigates ongoing market challenges.","metaDescription":"Johnson & Johnson (JNJ) Q4 2024 earnings: EPS beat by 1.85%. Stock down 1.94%. Full breakdown."}}